“Your body holds deep wisdom. Trust in it. Learn from it. Nourish it. Watch your life transform and be healthy.”

– Bella Bleue 

PNA Spotlight: Dr. Yuval Eisenberg

This month the PNA Spotlight shines on Dr. Yuval Eisenberg.  Dr. Eisenberg graduated from Rush Medical College at Rush University Medical Center in 2009. He works in Chicago, IL and two other locations and specializes in internal medicine as well as endocrinology, diabetes & metabolism. Dr. Eisenberg is also affiliated with the University of Illinois Hospital Health & Science Center.  He was kind enough to answer some of our questions:

 

What inspired you to choose your career path?

My career path was guided by my interaction with patients and my mentors. The highlight of my medical school training was helping to diagnose a young man suffering from multiple endocrine neoplasia type 1 (MEN1), a rare genetic disorder causing multiple tumors, including a pituitary adenoma. Listening to his concerns and thinking outside the box, I helped provide him with the correct diagnosis and treatment plan – and started my journey into endocrinology. I have been fortunate to work with excellent clinician-educators in my career. Learning about and observing the care of patients with endocrine-related problems was fascinating and rewarding. The farther I got in my training, the more I realized that endocrinology was my passion and that patients with pituitary disorders would be my sub-focus. Patients with pituitary disease are a unique population who are in need of education, support and reassurance at diagnosis – and they often require long-term follow-up. This allows for time to develop a bond of trust; an aspect of medical practice I thoroughly enjoy.

Read More Here

 

Safeguarding the nose during pituitary tumor surgery

Pituitary tumors are typically removed through the nose during endoscopic transnasal transsphenoidal surgery. Although minimally invasive, that approach requires expertise to minimize surgical trauma to the nose. Fortunately, surgeons are using new techniques that help safeguard the nose and maximize patients’ quality of life after surgery.

“The tendency now is to be less invasive in the approach through the nose,” explains Dr. Carlos D. Pinheiro Neto, a Mayo Clinic ENT/head and neck surgeon. “A very aggressive approach can cause chronic nasal crusting and infections, scabbing, decreased sense of smell and taste, and changes in the nose’s appearance.”

In endoscopic transnasal transsphenoidal surgery, a small surgical camera and surgical instruments are placed through the nostrils to access the tumor through the sinuses. Mayo Clinic was among the first institutions to extensively research the approach. As initially developed, the procedure involved extensive nasal resection.

“The idea was to create a maximum opening of the sinuses to allow neurosurgeons to reach and remove the tumor from the skull base,” Dr. Pinheiro Neto says. “The nasal physiology and sinus symptoms after the surgery were not a priority — the nose was just a corridor to the tumor.”

Now, Dr. Pinheiro Neto is pioneering surgical techniques that minimize resection of the nasal and sinus structures. One involves leaving intact the middle turbinate, which plays important roles in nasal airflow, warming and filtering air to the lungs, and smelling. Another is using a nasal-floor graft to provide a seal between the nose and brain after tumor removal. The standard procedure when cerebrospinal fluid leaks during surgery involves a nasal septal flap created from the septum — the tissue that separates the nostrils’ two airways.

“Nasal graft is much better for patients. It avoids the exposure of the nasal septum cartilage, so there is less crusting and faster healing,” Dr. Pinheiro-Neto says. “Nasal septal flaps can also cause a structural collapse in the nasal bridge and increase the risk of septal perforations. Since changing our paradigm from nasal septal flap for pituitary surgery, our leak rate is 0.1%.”

The new techniques are based on research conducted in Mayo Clinic’s anatomy laboratory. Those lessons are translated to the operating room, where ENT/head and neck surgeons routinely work alongside neurosurgeons to remove pituitary tumors.

“That research has allowed us to achieve the same level of tumor resection and treatment outcomes, but with fewer complications,” Dr. Pinheiro-Nato says. “With time and experience, we have realized it’s possible to preserve most of the nose and still get good space in the back of the sinus for tumor removal.

“This is about improving patients’ quality of life,” Dr. Pinheiro-Neto says. “They can have a nasal procedure but after a few weeks of healing, the nose and nasal physiology, and the sinuses, are as good as ever before.”

Stanford Hosts Pituitary Patient Education Day

Stanford University invites the public to their free pituitary patient education day, to be held both in-person and via zoom on Saturday November 9th, 2024. The event will run from 8am-5pm and will take place in the Assembly Hall at Stanford Hospital.

The course co-directors include neurosurgeon Juan C. Fernandez-Miranda, MD (a longtime member of the PNA), and endocrinologist Julia Chang, MD. Topics to be discussed include the function of the pituitary gland, endonasal endoscopic surgery, cavernous sinus surgery, radiotherapy, Cushing’s, acromegaly, prolactinoma and more.

Click To Sign Up Here

Featured News and Updates

News Articles April 2026

Pituitary story: 10-year-old pituitary patient honored for bravery

 A ten-year-old Scottish girl has been honored for her bravery as she underwent surgery for a pituitary tumor. Read more:  https://www.northern-times.co.uk/news/she-s-an-absolute-star-inverness-pupil-honoured-for-brave-431104/

Teen overcomes Cushing’s Disease

 

A 17-year-old girl in North Carolina is doing well after surgery to remove a pituitary tumor caused by Cushing’s Disease. She is an avid runner who suffered headaches and fatigue before her diagnosis.  Read more: https://www.wect.com/2026/04/01/believe-them-teen-runner-diagnosed-with-rare-cushings-disease-after-years-symptoms/

 

Pituitary story: Cushing’s at age 27

A 27-year-old woman experienced a lack of menses and unexplained weight gain before being diagnosed with Cushing’s disease. She had surgery at Cleveland Clinic in Florida and has returned to a normal life. Read more: https://my.clevelandclinic.org/patient-stories/960-in-her-twenties-yoselin-needed-pituitary-tumor-surgery

 

 

Mobile MRI during pituitary surgery

An article on MSN.com looks at the use of mobile brain scanners during pituitary surgery in Canada.  Read more: https://www.msn.com/en-ca/health/other/mobile-brain-scans-sound-like-science-fiction-but-they-re-now-helping-more-canadian-patients/ar-AA1YlZWc

Research Articles

Research Articles April 2026

Pituitary Tumors

Astragaloside IV targets TUBB4B to inhibit proliferation and promote apoptosis of pituitary tumor cells via the STMN1/ERK pathway.

Li J, Qu Y, Zhang W, Yang Z, Zeng Y, Xu J, Xie K, Liu Q.Int J Mol Med. 2026 Jun;57(6):151. doi: 10.3892/ijmm.2026.5822. Epub 2026 Apr 3.

 

[Endocrine inactive pituitary microadenomas: current data on natural history and follow-up approaches].

Dzhatieva DN, Pigarova EA, Dzeranova LK.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):98-102. doi: 10.17116/neiro20269002198.


[Impact of cabergoline on fibrosis in prolactinoma].

Matsueva IA, Paltsev AA, Guseva KA, Tsoy UA, Grineva EN.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):85-91. doi: 10.17116/neiro20269002185.


[Hypothalamic obesity in adults with craniopharyngiomas: prevalence and risk factors before and after neurosurgical treatment].

Klochkova IS, Astafyeva LI, Kutin MA, Konovalov AN, Sidneva YG, Shkarubo AN, Kalinin PL.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):77-84. doi: 10.17116/neiro20269002177.

 

Gonadal recovery in men with prolactinomas on cabergoline: 6-month testosterone levels as a predictor of testosterone replacement timing.

Fedai NK, Uzun N, Bostan H, Kizilgul M, Demirci T, Cakal E, Ucan B.Hormones (Athens). 2026 Apr 2. doi: 10.1007/s42000-026-00766-3. Online ahead of print.


Visual outcomes after pituitary adenoma surgery: Associated factors and longitudinal progression in a prospective single-centre study.

Lozouet M, Saadoun A, Ménard A, Aldea S, Jaoude SA, Heran F, Yavchitz A, Philibert M, Chauvet D.Clin Neurol Neurosurg. 2026 Mar 28;267:109409. doi: 10.1016/j.clineuro.2026.109409. Online ahead of print.

 

Machine Learning-Based models in prediction of Ki-67 in pituitary adenoma: A systematic review and Meta-Analysis.

Hajikarimloo B, Mohammadzadeh I, Tos SM, Bahri A, Sabaghian A, Habibi MA.Endocrine. 2026 Apr 1;91(1):118. doi: 10.1007/s12020-026-04590-y.

 

Pituitary disorders

Recurrent pituitary apoplexy: experience from a national registry and review of the literature.

Biagetti B, Cordero Asanza E, Iglesias P, Camara R, Asla Q, Vicente A, Martinez-Saez E, Sarria-Estrada S, Puig-Domingo M, Araujo-Castro M.Ther Adv Endocrinol Metab. 2026 Mar 28;17:20420188261434641. doi: 10.1177/20420188261434641. eCollection 2026.


Post-Traumatic Pituitary Stalk Transection Syndrome.

Albusaidi R, AlHatmi A, Al Shidhani A, Al-Ajmi E.Sultan Qaboos Univ Med J. 2026 Mar 7;26(1):230-232. doi: 10.18295/2075-0528.2977. eCollection 2026.


The impact of a non-functioning pituitary adenoma on life – A qualitative study of patients’ experiences.

Al-Shamkhi N, Edén Engström B, Rask E, Anderzén-Carlsson A.PLoS One. 2026 Mar 31;21(3):e0345909. doi: 10.1371/journal.pone.0345909. eCollection 2026.

 

Combined surgery and proton radiotherapy in the management of craniopharyngiomas: an update with paradigmatic and challenging case scenarios.

Valeri F, Zoli M, Lillo S, Tengattini F, Colombo F, Pasquini E, Salierno G, Carretta A, D’Ambrosio L, Babaei D, Agosti E, Mattogno PP, Fontanella MM, Lauretti L, Mazzatenta D, Doglietto F, Iannalfi A.Neurosurg Rev. 2026 Mar 31;49(1):331. doi: 10.1007/s10143-026-04258-1.

 

Cushing’s

Traditional Chinese Medicine in Cushing’s Syndrome: A Narrative Review of Pathophysiology and Potential Therapeutic Effects.

Chen B, He C, Han L, Wang H, Ma Y, Wang R, Cai X.Onco Targets Ther. 2026 Feb 6;19:571776. doi: 10.2147/OTT.S571776. eCollection 2026.

 

Symptom management with osilodrostat in multiple endocrine neoplasia type 1 with a Cushing syndrome presentation.

Jamal HF.JCEM Case Rep. 2026 Mar 31;4(4):luag039. doi: 10.1210/jcemcr/luag039. eCollection 2026 Apr.


Persistent remission after steroidogenesis inhibitor discontinuation in Cushing disease: a case series.

Mangone A, Sala E, Carosi G, Sindaco GD, Mungari R, Cremaschi A, Petria I, Noschese G, Lotito V, Mantovani G, Ferrante E.Pituitary. 2026 Apr 1;29(2):68. doi: 10.1007/s11102-026-01668-8.

 

Clinical characteristics, diagnosis, and treatment of Cushing’s syndrome: analysis of a multicenter registry in Antioquia, Colombia.

Rivera-Martínez WA, Ramírez Castaño MJ, Cruz Calderón S, Díaz Posada NA, Gutiérrez Restrepo J, Román-González A, Aristizábal Henao N, Castaño Ceballos PA, Tobón Ospina CI, Donado Gómez JH, López Pompey N, Builes-Montaño CE.Ther Adv Endocrinol Metab. 2026 Mar 28;17:20420188261434078. doi: 10.1177/20420188261434078. eCollection 2026.


Prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease in Craniopharyngioma Patients Using Non-Invasive Investigations.

Nitya AAV, Ghosh J, Taneja S, Singla V, Kalra N, Dutta P.Indian J Endocrinol Metab. 2026 Jan-Feb;30(1):79-84. doi: 10.4103/ijem.ijem_821_25. Epub 2026 Feb 27.


A proposed classification and scoring system predicting gross total resection of recurrent and residual pituitary adenoma: a retrospective study.

Quan W, Zhao DW, Li L, Chen HR, Wang L, Hu SL, Hu R.World Neurosurg. 2026 Mar 28:124958. doi: 10.1016/j.wneu.2026.124958. Online ahead of print.PMID: 41912140

 

 

Acromegaly

Meningoencephalitis and secondary pituitary abscess in a 16-year-old patient with gigantism.

Wissa M, Strenger V, Weinhandl G, Braun H, Wolfsberger S, Micko A.JCEM Case Rep. 2026 Apr 1;4(4):luag032. doi: 10.1210/jcemcr/luag032. eCollection 2026 Apr.

 

The silent surden: Alexithymia and quality of life in acromegaly patients.

Soltanova L, Aygun AB, Kocaman BB, Muradov I, Taze SS, Turan S, Kadioglu P, Durcan E.Endocrine. 2026 Apr 2;91(1):135. doi: 10.1007/s12020-026-04606-7.

 

To test or not to test: what we have learnt from 50 years of dynamic testing in acromegaly.

De Marinis L, Chiloiro S, Mancini A, Giambò P, Giampietro A, Bianchi A, Pontecorvi A, Giustina A.Pituitary. 2026 Mar 31;29(2):67. doi: 10.1007/s11102-026-01649-x.


Acromegaly is Associated with an Increased Incidence of Primary Malignant Tumors: Data from a National Study in Sweden.

Tsatsaris E, Robèrt J, Burman P, Berinder K, Bonelli L, Dahlqvist P, Höybye C, Ragnarsson O, Vouzouneraki K, Åkerman AK, Ekman B, Engström BE.J Clin Endocrinol Metab. 2026 Mar 30:dgag137. doi: 10.1210/clinem/dgag137. Online ahead of print.PMID: 41913644

 

Acromegaly-Physiopathology and etiology.

Castinetti F.Vitam Horm. 2026;131:83-102. doi: 10.1016/bs.vh.2026.01.001. Epub 2026 Jan 28.PMID: 41912301 Review.

 

Co-secreting pituitary adenomas in acromegaly: Classification, diagnosis, and treatment strategies.

Biagetti B, Araujo-Castro M.Vitam Horm. 2026;131:41-57. doi: 10.1016/bs.vh.2025.06.002. Epub 2025 Dec 3.


Acromegaly and histopathology.

Caballero GA, Ribalta T, Aldecoa I.Vitam Horm. 2026;131:293-334. doi: 10.1016/bs.vh.2025.10.007. Epub 2025 Nov 13.PMID: 41912298 Review.


New molecular markers of response to medical therapy in acromegaly.

Raventós A, Gil J, Marques-Pamies M, de Pedro-Campos P, Puente de la Vega C, Picó A, Lamas C, Delgado E, Menéndez E, Serra G, Bernabéu I, Villar R, Ferri J, Mariaca K, Martínez R, Marazuela M, Araujo-Castro M, Biagetti B, Jordà M, Valassi E, Puig-Domingo M; ACROMICS investigators.Vitam Horm. 2026;131:265-292. doi: 10.1016/bs.vh.2025.10.006. Epub 2025 Nov 12.

 

Acromegaly and genetics.

de Lapiscina IM, Baquero C, Castaño L.Vitam Horm. 2026;131:235-263. doi: 10.1016/bs.vh.2025.10.008. Epub 2025 Dec 16.PMID: 41912295 Review.

 

Gigantism.

Donato S, Regala C, Marques P.Vitam Horm. 2026;131:195-234. doi: 10.1016/bs.vh.2025.10.005. Epub 2026 Feb 16.PMID: 41912294 Review.

 

Hormonal Health

Male testosterone synthesis disorders: oxidative stress pathways, regulatory mechanisms, potential of antioxidant therapy, and botanical medicine prospects.

Wu H, Jian MT, Ning G, Li BN, Peng AJ, Wang HY, Tang X, Zhou X.Asian J Androl. 2026 Apr 3. doi: 10.4103/aja2025105. Online ahead of print.

 

From the perspective of prolactin: a view on obesity.

Wang Y, Luo D, Fang G, Ge M, Huang Y, Deng H.Front Endocrinol (Lausanne). 2026 Mar 16;17:1762596. doi: 10.3389/fendo.2026.1762596. eCollection 2026.

 

Gonadotropins Across the Lifespan: Their role in the Neurodevelopment-Neurodegeneration Continuum.

Galbraith JA, Elhassan MZ, Rocha JF, Al Mozani TA, Fredericks CA.Yale J Biol Med. 2026 Mar 31;99(1):199-215. doi: 10.59249/EVST3084. eCollection 2026 Mar.

 

Neonatal Hypopituitarism.

Dayno AN, Crowley J, Bamba V, Bhoj EJK, Shekdar K, McCormack SE.Neoreviews. 2026 Apr 1;27(4):e211-e221. doi: 10.1542/neo.27-4-002.

 

Unconventional Uses of Human Growth Hormone.

Lisbona-Buzali M, Edid-Jaris G, Alegre-Lifshitz A, Mercado-Medrez S, Taniguchi-Ponciano K, Marrero-Rodriguez D, Mercado M.Arch Med Res. 2026 Mar 30;57(5):103412. doi: 10.1016/j.arcmed.2026.103412. Online ahead of print.PMID: 41915988 Review.

 

Comment on: Oxytocin: a neglected hormone in pituitary disease – From function to the diagnosis of a deficiency, resulting clinical relevance, and potential treatment options in endocrinology.

Elia A.Arch Endocrinol Metab. 2026 Jun 1;70(3):e260025. doi: 10.20945/2359-4292-2026-0025.

 

TRH can stimulate the release of two POMC-derived pituitary hormones, ACTH and MSH, in medaka.

Yamakawa M, Gajbhiye DS, Golan M, Kanda S.Endocrinology. 2026 Mar 30:bqag037. doi: 10.1210/endocr/bqag037. Online ahead of print.

 

 

 

 

Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support

Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.

Sign up to get dedicated support:

Patients: Sign up for support | Recorlev® (levoketoconazole)

HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)

Have more questions? Call for more support at 1-844-444-RCLV (7258)

Copyright © 2024 Pituitary Network Association All rights reserved.

Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]

You are receiving this Newsletter because you have shown interest in receiving information about our activities.

If you do not want to receive any more emails from PNA, Unsubscribe.